Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/18—Growth factors; Growth regulators
  • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B11/00—Preparation of cellulose ethers
  • C08B11/02—Alkyl or cycloalkyl ethers
  • C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
  • C08B11/10—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals
  • C08B11/12—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals substituted with carboxylic radicals, e.g. carboxymethylcellulose [CMC]
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
  • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
  • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
  • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
  • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
  • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
  • C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
  • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
  • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
  • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
  • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
  • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates

Definitions

• the present invention relates to the formation of novel water-soluble complexes between an amphiphilic polymer and an osteogenic protein belonging to the family of Bone Morphogenetic Proteins, BMPs, physically and chemically stable complexes and thereby improving the physical and chemical stability of BMPs, at the both in vitro and in vivo.
• BMPs Bone Morphogenetic Proteins
• OPs Osteogenic Proteins
• BMPs are expressed as propeptides which, after post-translational processing, have a length of between 104 and 139 residues. They have a great homology of sequences between them and have similar three-dimensional structures. In particular, they have 6 cysteine residues involved in intramolecular disulfide bonds forming a "cysteine knot" (Scheufler C. 2004 J. Mol Biol 1999, 287, 103, Schlunegger MP, J. Mol Biol 1993, 231, 445). Some of them have a 7 th cysteine also involved in an intermolecular disulfide bridge responsible for dimer formation (Scheufler C. Mol Biol 2004 J. 1999; 287:... 103).
• BMPs In their active form, BMPs assemble into homodimers or even heterodimers as described by Israel et al. (Israel Dl, Growth Factors, 1996, 13 (3-4), 291). Dimeric BMPs interact with BMPR transmembrane receptors (Mundy et al., Growth Factors, 2004, 22 (4), 233). This recognition is at the origin of a cascade of intracellular signaling involving Smad proteins in particular resulting in the activation or repression of target genes. BMPs, with the exception of BMPs 1 and 3, play a direct and indirect role in the differentiation of mesenchymal cells causing their differentiation into osteoblasts (Cheng H., J. Bone and Joint Surgery, 2003,
• recombinant human BMPs and in particular rhBMP-2 and rhBMP-7, have clearly demonstrated an ability to induce bone formation in vivo in humans and have been approved for certain medical applications.
• recombinant human BMP-2 dibotermin alfa according to the international nonproprietary name, is formulated in products sold under the name Infuse ® in the US and InductOs ® in Europe. This product is prescribed in the fusion of the lumbar vertebrae and the bone regeneration of the tibia for so-called non-union fractures.
• the surgical procedure consists first of all, to soak a collagen sponge with a solution of rhBMP-2, then to place the sponge in a hollow cage, LT Cage, previously implanted between the vertebrae.
• OP-1 Implant Human recombinant BMP-7, eptotermin alpha according to the international nonproprietary name, has the same therapeutic indications as BMP-2 and is the basis of two products: OP-1 Implant for open fractures of the tibia and OP-1 Putty for the fusion of the lumbar vertebrae.
• OP-1 Implant consists of a powder containing rhBMP-7 and collagen to be taken up in 0.9% saline solution. The paste obtained is then applied to the fracture during a surgical procedure.
• OP-1 Putty comes in the form of two powders: one containing rhBMP-7 and collagen, the other carboxymethylcellulose (CMC). During surgery, CMC is reconstituted with 0.9% saline and mixed with rhBMP-7 and collagen. The paste thus obtained is applied to the site to be treated.
• CMC carboxymethylcellulose
• BMPs are distinguished by their high hydrophobicity and their ability to aggregate, which leads to a very low solubility at physiological pH.
• BMP-2 these properties have been documented in the studies that have been used in its clinical development. It is poorly soluble in physiological conditions and tends to aggregate (Schmoekel, 2004 J. Orthop.Res.2004, 22 (2), 376, Friess, W., Drug Delivery Systems Based on Collagen, Shaker Verlag, Thesis Aachen Germany 1999, Schwartz DH, Thesis Kunststoff Germany 2005).
• Abbatiello and Porter Protein Sci., 1997, 6, Suppl 2 99 have shown that BMP-2 in a low ionic strength buffer becomes increasingly insoluble as pH increases beyond 4.5.
• the precipitation of the protein is observed for a pH greater than 6.5 but also at lower pH in the presence of chloride and / or sulfate ions (pH 5.8 at 50 mM NaCl, and pH 5.5 at 5 mM Na2SO4). has been shown by Friess (Friess, W., Drug Delivery Systems Based on Collagen, Shaker Verlag, Thesis Aachen Germany 1999). The formulation of BMP-2 under physiological conditions is therefore a problem in its own right.
• the product InFUSE ® had to be formulated at acid pH (acetic acid buffer, pH 4) and in the presence of a surfactant, polysorbate 80 to ensure the solubility and physical stability of rhBMP-2.
• BMP very large BMP
• This large amount of BMP to administer involves having to work at high concentrations of BMP in solution, of the order of 1.5 mg / ml. At these concentrations, BMPs aggregate very easily and are therefore not physically stable.
• the solutions used use acidic buffers and surfactants. From the point of view of the therapeutic application, the use of an acidic solution containing surfactants is problematic.
• heparin and heparan sulphates are well known for stabilizing growth factors including BMPs since these polysaccharides are endogenous stabilizing molecules (Ruppert et al., J. Biochem 1996, 237, 295). .
• heparin and heparan sulphates have a very high anti-coagulant and anti-complementary activity and can not therefore be used in a pharmaceutical composition.
• Hubbell has described a protein grafting approach that involves creating a chemical bond between the protein and a vector to stabilize it in a fibrin-like matrix. This binding is established through an enzyme cleavable fusion protein. This path, reported in the publication Biotechno. Bioeng. 2005, 89, 3, 253, actually helps to physically stabilize the protein by preventing aggregation. However, this route leads to the use of a BMP-2 analogue that has not yet demonstrated its therapeutic efficacy and safety.
• amphiphilic peptides for the vectorization of growth factors, and in particular BMP-2.
• These amphiphilic peptides consist of a terminal alkyl chain, a hydrophilic peptide sequence and an epitope allowing adhesion of BMP-2.
• These peptides are organized in solution to form stick-type macromolecular structures in which the hydrophobic groups are clustered in the core.
• the amino acids at the periphery make it possible to bring compatibility with the water and the adhesion of the protein.
• these peptides present an immunological risk because of their complex primary structure.
• Takaoka et al. have focused on the vectorization of BMP for bone regeneration applications in US6258382. These authors have developed new polymers based on lactic acid and / or glycolic, p-dioxanone, polyethylene glycol to control the release of these proteins. However, these authors do not address any problems related to this growth factor, in terms of physical or chemical stability. In addition, these polymers are not soluble in water but adsorb water to form gels. These polymers, on the other hand, are soluble in organic medium and are solubilized in acetone. The preparation of the polymer-BMP-2 formulation therefore requires the use of an organic solvent, which represents a risk of denaturation of the protein (Nature Biotechnology, 2001, 19, 332).
• Wyeth discloses hyaluronans modified with a hydrophobic group, benzyl alcohol, for the vectorization of BMPs.
• the level of hydrophobic group is between 50 and 100% so that the polymer is not soluble in water but can adsorb water.
• these hygroscopic polymers can not form a water-soluble complex with the protein making it possible to solve the stability problems of the BMPs.
• Formulations of the same type are also described in EP1454640 in the name of Fidia and Genetics Institute, however the described formulations do not form no complexes, the exemplified polysaccharides are insoluble in water and comprise more than 50% hydrophobic ester groups.
• Brodbeck et al. use PLAGA for vectorization of BMPs. These polymers are insoluble in water and therefore can not form a water-soluble complex with the protein.
• the objective of the authors is, contrary to the plaintiff, to insolubilize, in aqueous medium, the BMP in a solid consisting of PLAGA which again requires the use of an organic solvent which represents a risk of denaturation of the protein.
• CM carboxymethyl
• B benzylamide
• S sulfonate
• the galenic formulation of such proteins intended for bone reconstruction must necessarily meet the requirements of safety of the excipients and to reach these requirements, it is essential to use compounds that are biocompatible but also to limit the amount relative to active ingredient.
• BMPs selected from the group consisting of BMP-2 (Dibotermine-alpha), BMP-4, BMP-7 (Eptotermin -alpha), BMP-14 and GDF-5 are not satisfactorily resolved.
• the present invention makes it possible to form a stable water-soluble complex between osteogenic proteins and a biocompatible amphiphilic polymer with a mass / BMP mass ratio of less than 700.
• This complex makes it possible:
• This water-soluble complex is formed in a totally aqueous medium without resorting to the use of organic solvent.
• the present invention therefore relates to a water-soluble, physically and chemically stable, amphiphilic-BMP polymer complex characterized in that:
• amphiphilic polymers consist of a hydrophilic polysaccharide backbone functionalized with hydrophobic substituents and hydrophilic groups according to the following general formula I:
• R, R ' identical or different, represent a bond or a chain comprising between 1 and 18 carbons, optionally branched and / or unsaturated comprising one or more heteroatoms, such as O, N and / or S,
• F, F ' which are identical or different, represent an ester, a thioester, an amide, a carbonate, a carbamate, an ether, a thioether or an amine,
• X represents a hydrophilic group chosen from the group consisting of carboxylates, sulphates, sulphonates, phosphates, phosphonates,
• Y represents a hydrophilic group chosen from the group consisting of sulphates, sulphonates and phosphates of phosphonates,
• Hy represents a hydrophobic group selected from the group consisting of: linear or branched C8 to C30 alkyls, optionally unsaturated and / or containing one or more heteroatoms, such as O, N or S. alkylaryls or linear arylalkyls or branched C8 to C18, optionally unsaturated and / or optionally containing one or more heteroatoms, such as O, N or S. o optionally unsaturated C8 to C30 polycycles, and / or optionally containing one or more heteroatoms, such as O, N or S, o excluding benzylamine. • n and o are between 1 and 3,
• H represents the mole fraction of hydrophobic unit with respect to a saccharide unit of between 0.01 and 0.5
• X represents the mole fraction of hydrophilic groups with respect to a saccharide unit, between 0 and 2.0.
• Y represents the mole fraction of hydrophilic groups relative to a saccharide unit, between 0 and 0.5.
• ⁇ * BMP is selected from the group of therapeutically active BMPs (Bone Morphogenetic Proteins),
• the polymer / BMP mass ratio is less than or equal to 700.
• the polysaccharide is chosen from polysaccharides of general formula I, as defined above, in which X represents a carboxylate.
• the polysaccharide according to the invention is characterized in that the group R is chosen from the following groups:
• it relates to a complex characterized in that the polymer / BMP mass ratio is less than or equal to 600. In one embodiment, it relates to a complex characterized in that the polymer / BMP mass ratio is less than or equal to 500.
• the concentration of therapeutic BMP is about 1.5 mg / ml in solution.
• compositions comprising 1.0 g / ml of amphiphilic polymer are obtained. From such polymer concentrations, the formulations have a physicochemical behavior which is no longer suitable for pharmaceutical application, for example in terms of viscosity.
• BMP is chosen from the group consisting of BMP-2 (Dibotermin-alpha), BMP-4, BMP-7 (eptotermin alpha), BMP-14 and GDF-5. .
• the substituents of the amphiphilic polymers are distributed in a controlled or statistical manner.
• the polymers having a controlled distribution of substituents there may be mentioned, for example, alternating block copolymers and copolymers.
• the invention also relates to an amphiphilic polymer-BMP complex characterized in that the polymer is chosen from polymers whose substituents are randomly distributed.
• the polysaccharides are selected from the group consisting of hyaluronans, alginates, chitosans, galacturonans, chondroitin sulfate, dextrans, celluloses.
• the group of celluloses consists of celluloses functionalized with acids such as carboxymethylcellulose.
• the group of dextrans consists of dextrans functionalized with acids such as carboxymethyldextran.
• the polysaccharides are selected from the group consisting of hyaluronans, alginates, chitosans.
• R CH 2 COOH or H, Carboxymethyl Dextran
• the polysaccharide may have an average degree of polymerization m of between 10 and 10,000.
• it has an average degree of polymerization m of between 10 and 1000.
• it has an average degree of polymerization m of between 10 and 500.
• the invention also relates to an amphiphilic polymer-BMP complex characterized in that the hydrophobic group Hy is chosen from the group consisting of hydrophobic amino acids of natural origin, chosen from the group consisting of tryptophan, tyrosine, phenylalanine, leucine or isoleucine or their derivatives alcohols, esters, decarboxylates or amides.
• the hydrophobic group Hy is chosen from the group consisting of hydrophobic amino acids of natural origin, chosen from the group consisting of tryptophan, tyrosine, phenylalanine, leucine or isoleucine or their derivatives alcohols, esters, decarboxylates or amides.
• the invention also relates to an amphiphilic polymer-BMP complex characterized in that the hydrophobic group Hy is tryptophan or an ester or amide derivative of tryptophan.
• Tryptophan derivatives include tryptophanol, tryptophanamide and 2-indole-ethylamine.
• amphiphilic-BMP polymer complex according to the invention is reversible.
• the polymers used are synthesized according to the techniques known to those skilled in the art or purchased from suppliers such as, for example, Sigma-Aldrich, NOF Corp. or CarboMer Inc.
• the BMPs are chosen from recombinant human BMPs, obtained according to the techniques known to those skilled in the art or purchased from suppliers such as, for example, Research Diagnostic Inc. (USA).
• BMP is a very hydrophobic growth factor. At physiological pH, the hydrophobicity of this protein leads to aggregation followed by precipitation.
• the amphiphilic polymer-BMP complexes according to the invention make it possible to physically stabilize this protein in solution at physiological pH.
• physical or chemical degradation is meant any event of a physical nature, such as aggregation, or chemical, such as proteolysis, leading to a decrease in the biological activity of the protein.
• the physical or chemical stabilization of the protein is understood to mean the action of maintaining the biological activity of the protein.
• the stability of the complex is followed by measuring the stability of the BMP.
• a test for the detection of the amphiphilic polymer-BMP complex by gel coelectrophoresis "A thermal stability test of the BMP in the presence of cells in the amphiphilic-BMP polymer complex carried out at 37 ° C. and at neutral pH; and a physical stabilization test of the BMP in said complex at physiological pH.
• the test for the detection of the amphiphilic-BMP polymer complex by coelectrophoresis is based on the displacement of ions under the effect of an electric field.
• the anionic complexes migrate towards the anode and the cationic complexes move towards the cathode.
• the proteins are transferred by capillarity onto a PVDF membrane and revealed by an antibody specific for the protein recognized by a second antibody coupled to peroxidase.
• the protein alone does not migrate, the protein complexed with the amphiphilic polymer migrates towards the anode or the cathode as a function of the overall charge of the complex.
• the thermal stability test of the BMP in the presence of cells is carried out at 37 ° C. - neutral pH and consists in depositing a solution of BMP in a culture medium containing C2C12 myoblasts.
• the concentration of BMP in solution is determined by ELISA after the deposition (J2) and after 5 days of culture (J7).
• the biological activity of BMP is evaluated by assaying the activity of alkaline phosphatase produced between D2 and D7 during the differentiation of myoblasts into osteoblasts.
• the physical stabilization test of a BMP at physiological pH is based on the physiological pH of a protein solution by exchange of the original buffer of the protein, generally at acidic pH, with a solution of
• the amphiphilic-BMP polymer complex according to the invention is formed by the aqueous solution of a BMP and an amphiphilic polymer at physiological pH in the absence of any organic solvent capable of denaturing. the protein.
• the formation of the amphiphilic polymer-BMP complex is spontaneous and does not involve a covalent bond between the BMP and the amphiphilic polymer. This association is by weak bonds which are essentially hydrophobic interactions and ionic interactions. This complex formation does not require any organic solvent.
• One of the problems solved by the invention is an increased stabilization of the protein and therefore the maintenance of the biological activity in vitro and in vivo.
• This biological activity can be evaluated by various tests demonstrating the ability of a BMP to differentiate myoblasts into osteoblasts.
• This differentiation can be measured by:
• the invention also relates to a therapeutic composition characterized in that it comprises an amphiphilic polymer-BMP complex according to the invention.
• composition that can be used in human or veterinary medicine.
• the pharmaceutical composition according to the invention is preferably a composition with local application which may be in the form of a solute, a gel, a cream, a lyophilisate, a powder or a paste .
• composition according to the invention when in the form of a paste, it is for example obtained from products such as carboxymethylcelluloses (CMC), tricalcium phospate and collagen.
• CMC carboxymethylcelluloses
• tricalcium phospate and collagen.
• excipients may be used in this invention to adjust the formulation parameters such as a pH adjusting buffer, an isotonicity adjusting agent, preservatives such as methyl parahydroxybenzoate, propyl parahydroxybenzoate, m-cresol, or phenol or an antioxidant such as L-lysine hydrochloride.
• the therapeutic composition is characterized in that it allows an administration of approximately 1.5 mg / ml of BMP.
• the present invention also relates to the use of an amphiphilic polymer-BMP complex according to the invention for the preparation of a therapeutic composition intended to induce bone formation in vivo.
• This amphiphilic polymer is synthesized from a carboxymethyl-dextran having a degree of carboxymethyl substitution per saccharide unit of 1.0 and an average molar mass of 60 kg / mol.
• the ethyl ester of tryptophan is grafted onto the acids of this polymer according to a conventional method of organic solvent coupling employing ethyl chloroformate and N-methyl morpholine.
• the polymer is purified by ultrafiltration.
• the final polymer is characterized by: x a degree of substitution at TrpOEt per saccharide unit of 0.45, determined by 1 H NMR in D 2 O / NaOD.
• This amphiphilic polymer is obtained by basic hydrolysis of PA 1. 1N sodium hydroxide (3.79 ml) is added to an aqueous solution of amphiphilic polymer 1 (64 ml at 31 mg / ml) to reach pH 12.7. The resulting solution is stirred overnight at room temperature. The polymer is purified by dialysis against water (NaCl 0.9% and H 2 O). The final polymer is characterized by: x a degree of substitution in TrpONa per saccharide unit of 0.45, determined by 1 H NMR in D 2 O / NaOD.
• This amphiphilic polymer is synthesized according to Example 1 from a carboxymethyl dextran having a degree of carboxymethyl substitution per saccharide unit of 1.0 and an average molecular weight of 60 kg / mol.
• the final polymer is characterized by: x a degree of substitution in PheOEt per saccharide unit of 0.45, determined by 1 H NMR in D 2 O / NaOD.
• This amphiphilic polymer is synthesized according to Example 1 from a carboxymethyl dextran having a degree of carboxymethyl substitution per saccharide unit of 1.0 and an average molecular weight of 60 kg / mol.
• the final polymer is characterized by: x a degree of substitution in TyrOMe per saccharide unit of 0.45, determined by 1 H NMR in D 2 O / NaOD.
• This amphiphilic polymer is synthesized from a dextransuccinic acid having a degree of substitution of succinic acid per saccharide unit of 1.0 and an average molar mass of 70 kg / mol obtained according to the article by (Sanchez-Chaves, Manuel et al. , Polymer 1998, 39 (13), 2751-2757.).
• the ethyl ester of tryptophan is grafted onto the acids of this polymer according to a conventional method of organic solvent coupling employing ethyl chloroformate and N-methyl morpholine. After dilution of the reaction medium in water and adjusting the pH to 7 by adding 1N NaOH, the polymer is purified by ultrafiltration.
• the final polymer is characterized by: x a degree of substitution at TrpOEt per saccharide unit of 0.45, determined by 1 H NMR in D 2 O / NaOD.
• This amphiphilic polymer is synthesized according to Example 1 from a carboxymethyl dextran having a degree of carboxymethyl substitution per saccharide unit of 1.0 and an average molecular weight of 60 kg / mol.
• the final polymer is characterized by
• the BMP-2 / PA solution is diluted to 20 th in migration buffer (tris-acetate solution at pH 7). 2 ⁇ l of the diluted solution are then added to 8 ⁇ l of water and 7 ⁇ l of loading buffer (glycerol, tris-acetate and bromophenol blue in water). These 17 .mu.l containing 10 ng of BMP-2 and 5 .mu.g of PA are deposited in a well of a 0.8% agarose gel. The electrophoresis tank is closed and the generator is set at 30V. The migration lasts 1 hour.
• migration buffer tris-acetate solution at pH 7
• loading buffer glycerol, tris-acetate and bromophenol blue in water
• the gel is transferred to a PVDF membrane placed on the anode under an electric field (20 minutes, 15V, Bio-Rad Trans-Blot SD).
• the membrane is saturated with skimmed milk for 1 hour at room temperature and then incubated with primary antibodies of BMP-2 (overnight at 4 ° C) and finally incubated with secondary antibodies, Rabbit anti goat HRP (1 hour at room temperature). ambient).
• the revelation is by reaction of HRP on Opti-4CN. Revelation is stopped when the staining is sufficient since the reaction product absorbs in the visible.
• BMP-2 forms a complex with PA
• the complex is detected as a single spot 0.7 cm from the deposit (migration to the anode).
• BMP-2 is alone or does not complex with PA, it is detected at the depot and therefore has not migrated.
• Each solution is then diluted 1/10 with a solution of 10 mM PBS at pH 7.4 and 300 mOsm and then reconcentrated by centrifugation on a Microcon cell (YM10, 10 kD, 500 ⁇ l). This operation is repeated twice. At the end of these three washes, each solution is centrifuged and the concentration of BMP-2 in the supernatant is determined by ELISA assay.
• Part of the BMP-2 solution at 0.084 mg / ml is not washed to serve as a control.
• Another part of the BMP-2 solution at 0.084 mg / ml undergoes three cycles of washing against a solution of 1 mM HCl (pH 3). This buffer is known to stabilize BMP-2 but is not compatible with a pharmaceutical application.
• the ELISA assay of the BMP-2 solution that has not been washed gives a BMP-2 concentration of 83.4 ⁇ g / ml. This value corresponds to 100% of BMP-2.
• concentrations determined by ELISA of the other solutions after the three washes against PBS are related to this value of the unwashed BMP-2.
• the percentages of BMP-2 found are summarized in the following table.
• APs capable of forming a complex with BMP-2 render BMP-2 stable at physiological pH.
• BMP-2 is no longer present in solution at physiological pH.
• the protein is no longer present in solution. Stability and biological activity of BMP-2 in the presence of Amphiphilic Polymer in culture medium at 37 ° C. and at physiological pH
• the C2C12 cells are inoculated (7000 cells / well) in 96-well culture plates containing DMEM at 10% FCS and 1% ATB and are then incubated for 24 hours.
• the medium is replaced by DMEM at 2% FCS and 1% ATB for 24 hours.
• the medium is replaced by DMEM at 2% FCS and 1% ATB supplemented with a solution of BMP-2 alone (0.3 ⁇ g / ml) or a solution of the BMP-2 / PA 1 complex (0.3 / 150 ⁇ g / ml). ml, ratio 1/500).
• the complex is prepared by dilution of BMP-2 and PA separately in DMEM at 2% FCS and 1% ATB.
• the protein / PA 1 mixture is allowed to stand for 1 h before deposition.
• the cells are washed twice with PBS and then lysed with 50 ⁇ l of lysis buffer and undergo 3 cycles of freezing (-80 ° C.) / thawing (37 ° C.).
• the enzymatic activity of alkaline phosphatase is measured in the lysates on a substrate, p-nitrophenyl phosphate which absorbs at 405 nm. This activity is reduced to the amount of protein measured by microBCA and is therefore expressed in nmol pnP / min. ⁇ g of protein.
• BMP-2 is stabilized by the complex under living conditions beyond 5 days whereas it is not stable alone over such a period.
• BMP-2 As the activity of BMP-2 is revealed by a slow process of cell differentiation, the BMP-2 complex is more active in vitro than BMP-2 alone.
• thermolysin represents 25% of the protein (mass / mass).
• the revelation is done by means of a westem-blot made from an SDS-15 gel. 7 .mu.l of each sample (containing 65 ng of BMP-2) are mixed with 7 .mu.l of Laemli loading buffer containing SDS. The samples are then denatured for 10 min at 95 ° C. and then deposited on SDS-15% gel. As a control, equivalent amounts of BMP-2 (65 ng) and Thermolysin (16.25 ng) are also deposited on the gel. The electrophoresis tank is closed and the generator is set at 125V. The migration lasts 1 hour 15. After migration, the gel is transferred to a PVDF membrane by a BioRad transfer system for 1 h at 100 volts.
• the membrane is then saturated with skimmed milk for 1 hour at room temperature and then incubated with primary anti-BMP-2 antibodies (overnight at 4 ° C) and finally incubated with secondary antibodies coupled to HRP (1 hour at ambient temperature).
• the revelation is by reaction of the HRP on Opti-4CN. Revelation is stopped when the staining is sufficient since the reaction product absorbs in the visible.
• BMP-2 has an isoelectric point of 8.5, which means that, at a physiological pH of 7.4, BMP-2 is close to its minimum solubility. This can be demonstrated by an experiment to neutralize an acid solution of BM P-2.
• a clear solution of BMP-2 at 1, 5 mg / ml is prepared in acid buffer (Infuse buffer, pH 4.5). This solution is neutralized by addition of a phosphate buffer to reach a pH of 7.4 (final BMP-2 concentration of 1.2 mg / mL). At pH 7.4, BMP-2 precipitated and the aggregates formed are visible. Neutralization led to a suspension.
• a clear solution of BMP-2 at 1, 5 mg / ml is prepared in acid buffer (Infuse buffer, pH 4.5). To this solution is added lyophilized PA2 to reach a PA2 concentration of 75 mg / mL. This BMP-2 / PA2 complex solution is then neutralized by adding a phosphate buffer to reach a pH of 7.4 (final concentration of BMP-2 of 1.2 mg / mL and 60 mg / mL of PA2). . At pH 7.4, BMP-2 is fully soluble and no aggregates are visible. The solubility of BMP-2 at physiological pH in the form of BMP-2 / PA2 complex is therefore greatly increased.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Biochemistry (AREA)
• Materials Engineering (AREA)
• Polymers & Plastics (AREA)
• Molecular Biology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Dermatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Inorganic Chemistry (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Rheumatology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Materials For Medical Uses (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=38990010

Family Applications (1)

Country Status (13)

Families Citing this family (31)

Family Cites Families (24)

• 2007
  • 2007-07-27 FR FR0705536A patent/FR2919188B1/fr not_active Expired - Fee Related
• 2008
  • 2008-07-25 CN CN200880107383A patent/CN101835493A/zh active Pending
  • 2008-07-25 BR BRPI0813025A patent/BRPI0813025A2/pt not_active IP Right Cessation
  • 2008-07-25 RU RU2010107203/15A patent/RU2010107203A/ru not_active Application Discontinuation
  • 2008-07-25 KR KR1020107004494A patent/KR20100051695A/ko not_active Application Discontinuation
  • 2008-07-25 AU AU2008281848A patent/AU2008281848A1/en not_active Abandoned
  • 2008-07-25 CA CA2694600A patent/CA2694600A1/fr not_active Abandoned
  • 2008-07-25 JP JP2010518637A patent/JP2010534708A/ja active Pending
  • 2008-07-25 WO PCT/EP2008/059832 patent/WO2009016131A1/fr active Application Filing
  • 2008-07-25 EP EP08786481A patent/EP2178565A1/fr not_active Withdrawn
  • 2008-07-25 MX MX2010001104A patent/MX2010001104A/es active IP Right Grant
  • 2008-07-25 US US12/219,679 patent/US8389661B2/en active Active
• 2010
  • 2010-02-17 ZA ZA201001163A patent/ZA201001163B/xx unknown

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events